JPMorgan Chase & Co. Has Lowered Expectations for Corteva (NYSE:CTVA) Stock Price

Key Points

• JPMorgan cut its Corteva price target from $19 to $16 but maintained an “overweight” rating; the new target implies 72.47% upside from the share price cited in the report.
• Other analysts also lowered targets: UBS reduced its target to $10 with a neutral rating, while RBC cut its target to $11 but retained an outperform rating. MarketBeat reported a consensus “Moderate Buy” rating.
• Brazil-related weakness is pressuring results: excess inventories, pricing pressure, and lower volumes have weighed on performance, and Corteva lowered its 2026 adjusted EPS outlook to $0.76–$0.80, below the cited analyst consensus of $1.07.

Corteva (NYSE:CTVA - Get Free Report) had its price target lowered by JPMorgan Chase & Co. from $19.00 to $16.00 in a report released on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target points to a potential upside of 72.47% from the company's current price.

A number of other brokerages also recently weighed in on CTVA. New Street Research set a $17.00 target price on Corteva in a report on Monday, October 5th. UBS Group lowered their price objective on shares of Corteva from $15.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday. Royal Bank Of Canada dropped their target price on shares of Corteva from $17.00 to $11.00 and set an "outperform" rating on the stock in a research report on Friday. Deutsche Bank reissued a "buy" rating and issued a $101.00 price objective on shares of Corteva in a research note on Monday, August 3rd. Finally, Bank of America upped their target price on Corteva from $90.00 to $96.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. Fifteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.27.

Corteva Price Performance

Shares of NYSE CTVA traded up $0.09 during midday trading on Friday, reaching $9.28. The company's stock had a trading volume of 14,193,068 shares, compared to its average volume of 8,320,709. The company has a market cap of $6.19 billion, a P/E ratio of 6.14, a P/E/G ratio of 1.69 and a beta of 0.58. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.10 and a current ratio of 1.52. The business's 50 day moving average price is $38.81 and its two-hundred day moving average price is $69.88. Corteva has a fifty-two week low of $9.01 and a fifty-two week high of $90.97.

Hedge Funds Weigh In On Corteva

Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Corteva during the 2nd quarter worth about $4,560,180,000. Wellington Management Group LLP boosted its position in shares of Corteva by 941.7% in the second quarter. Wellington Management Group LLP now owns 7,612,704 shares of the company's stock valued at $644,720,000 after acquiring an additional 6,881,875 shares during the period. Royal Bank of Canada boosted its position in shares of Corteva by 202.1% in the first quarter. Royal Bank of Canada now owns 7,458,624 shares of the company's stock valued at $624,362,000 after acquiring an additional 4,989,371 shares during the period. Jupiter Topco LLC purchased a new position in Corteva during the second quarter valued at approximately $544,246,000. Finally, Bank of America Corp DE bought a new stake in Corteva during the 2nd quarter worth approximately $484,927,000. Hedge funds and other institutional investors own 81.54% of the company's stock.

Key Headlines Impacting Corteva

Investors following CTVA have been watching these headlines:

• Neutral Sentiment: UBS cut its price target from $15 to $10 and maintained a neutral rating. RBC lowered its target from $17 to $11 but kept an outperform rating; both targets remain above the cited share price. UBS analyst rating RBC analyst rating
• Negative Sentiment: The main concern is persistent weakness in Brazil, including excess inventories and pricing pressure, which Corteva’s CEO expects to continue weighing on results. The company lowered its 2026 adjusted EPS guidance to $0.76–$0.80, below the cited analyst consensus of $1.07. Reports also point to lower volumes and competitive pricing contributing to weak quarterly performance. Article: Corteva shares slide after Brazil weakness prompts annual profit forecast cut Article: Corteva’s Q3 Earnings Miss Estimates on Brazil Weakness, Sales Lag
• Negative Sentiment: A law firm announced an investigation into possible securities-law violations related to Corteva. The announcement is not a finding of wrongdoing, but may add uncertainty for investors. Article: Securities fraud investigation announcement

Corteva Company Profile

Corteva, Inc. is an agricultural science company that develops and supplies products and services for farmers. Its business focuses on seeds and crop protection, including technologies intended to help improve crop performance and manage weeds, insects, and plant diseases. Its seed portfolio includes corn, soybean, and other crop varieties, sold under brands such as Pioneer and Brevant. Corteva's crop protection offerings include herbicides, insecticides, fungicides, and biological products, alongside digital tools and services that support farm decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.